Show simple item record

dc.contributor.authorSherratt, Samuel C. R.
dc.contributor.authorLero, Michael
dc.contributor.authorMason, R. Preston
dc.date2022-08-11T08:09:56.000
dc.date.accessioned2022-08-23T16:49:17Z
dc.date.available2022-08-23T16:49:17Z
dc.date.issued2020-04-01
dc.date.submitted2020-05-08
dc.identifier.citation<p>Curr Opin Lipidol. 2020 Apr;31(2):94-100. doi: 10.1097/MOL.0000000000000665. <a href="https://doi.org/10.1097/MOL.0000000000000665">Link to article on publisher's site</a></p>
dc.identifier.issn0957-9672 (Linking)
dc.identifier.doi10.1097/MOL.0000000000000665
dc.identifier.pmid32022752
dc.identifier.urihttp://hdl.handle.net/20.500.14038/41430
dc.description.abstractPURPOSE OF REVIEW: The purpose of this review is to assess whether dietary fish oil supplements can be appropriate for patients with elevated triglycerides and cardiovascular risk based on a comprehensive analysis of their composition, and level of regulatory oversight. RECENT FINDINGS: Approximately 19 million people in the United States take fish oil supplements, many for the purpose of treating or preventing heart disease. Unlike prescription products, fish oil supplements are classified as food by the Food and Drug Administration (FDA) and are not required to undergo manufacturing oversight or clinical testing. Analysis of widely used dietary fish oil supplements show that they may have lower amounts of omega-3 than advertised as well as significant levels of saturated fat and oxidized oils which actually may contribute to dyslipidemia. Clinical outcome trials have failed to show a consistent cardiovascular benefit with fish oil supplements and other low-dose mixed omega-3 fatty acids. SUMMARY: In light of limited regulatory oversight and evidence of quality concerns, dietary fish oil supplements are not an appropriate substitute for FDA approved prescription omega-3 fatty acids for their indicated use in treatment of elevated triglycerides or the prevention of cardiovascular events.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=32022752&dopt=Abstract">Link to Article in PubMed</a></p>
dc.rightsCopyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CC BY-NC-ND),where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectfish oil
dc.subjectoxidized lipids
dc.subjectsupplement
dc.subjectCardiology
dc.subjectCardiovascular Diseases
dc.subjectDietetics and Clinical Nutrition
dc.subjectHealth Services Administration
dc.subjectLipids
dc.subjectMolecular, Genetic, and Biochemical Nutrition
dc.subjectNutritional and Metabolic Diseases
dc.subjectTherapeutics
dc.titleAre dietary fish oil supplements appropriate for dyslipidemia management? A review of the evidence
dc.typeJournal Article
dc.source.journaltitleCurrent opinion in lipidology
dc.source.volume31
dc.source.issue2
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=5229&amp;context=oapubs&amp;unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/oapubs/4210
dc.identifier.contextkey17677186
refterms.dateFOA2022-08-23T16:49:17Z
html.description.abstract<p>PURPOSE OF REVIEW: The purpose of this review is to assess whether dietary fish oil supplements can be appropriate for patients with elevated triglycerides and cardiovascular risk based on a comprehensive analysis of their composition, and level of regulatory oversight.</p> <p>RECENT FINDINGS: Approximately 19 million people in the United States take fish oil supplements, many for the purpose of treating or preventing heart disease. Unlike prescription products, fish oil supplements are classified as food by the Food and Drug Administration (FDA) and are not required to undergo manufacturing oversight or clinical testing. Analysis of widely used dietary fish oil supplements show that they may have lower amounts of omega-3 than advertised as well as significant levels of saturated fat and oxidized oils which actually may contribute to dyslipidemia. Clinical outcome trials have failed to show a consistent cardiovascular benefit with fish oil supplements and other low-dose mixed omega-3 fatty acids.</p> <p>SUMMARY: In light of limited regulatory oversight and evidence of quality concerns, dietary fish oil supplements are not an appropriate substitute for FDA approved prescription omega-3 fatty acids for their indicated use in treatment of elevated triglycerides or the prevention of cardiovascular events.</p>
dc.identifier.submissionpathoapubs/4210
dc.contributor.departmentGraduate School of Biomedical Sciences
dc.source.pages94-100


Files in this item

Thumbnail
Name:
Are_dietary_fish_oil_supplemen ...
Size:
636.0Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CC BY-NC-ND),where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
Except where otherwise noted, this item's license is described as Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CC BY-NC-ND),where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.